Literature DB >> 24530120

High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and Beta-blocker overdose: a case series.

Bruce Doepker1, William Healy2, Eric Cortez3, Eric J Adkins4.   

Abstract

BACKGROUND: Recently, high-dose insulin (HDI) and intravenous lipid emulsion (ILE) have emerged as treatment options for severe toxicity from calcium-channel blocker (CCB) and beta blocker (BB).
OBJECTIVE: Our aim was to describe the use and effectiveness of HDI and ILE for the treatment of CCB and BB overdose. CASE REPORTS: We describe 2 patients presenting to the emergency department after intentional ingestions of CCBs and BBs. A 35-year-old man presented in pulseless electrical activity after ingesting amlodopine, verapamil, and metoprolol. A 59-year-old man presented with cardiogenic shock (CS) after ingesting amlodopine, simvastatin, lisinopril, and metformin. Both patients were initially treated with glucagon, calcium, and vasopressors. Shortly after arrival, HDI (1 unit/kg × 1; 1 unit/kg/h infusion) and ILE 20% (1.5 mL/kg × 1; 0.25 mL/kg/min × 60 min) were initiated. This led to hemodynamic improvement and resolution of shock. At the time of hospital discharge, both patients had achieved full neurologic recovery.
CONCLUSIONS: HDI effectively reverses CS induced by CCBs and BBs due to its inotropic effects, uptake of glucose into cardiac muscle, and peripheral vasodilatation. ILE is theorized to sequester agents dependent on lipid solubility from the plasma, preventing further toxicity. To our knowledge, these are the first two successful cases reported using the combination of HDI and ILE for reversing CS induced by intentional ingestions of CCBs and BBs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  beta blocker; calcium-channel blocker; high-dose insulin; lipid emulsion; overdose

Mesh:

Substances:

Year:  2014        PMID: 24530120     DOI: 10.1016/j.jemermed.2013.08.135

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  7 in total

1.  Too many pills to swallow: A case of a mixed overdose.

Authors:  Louise Emily Hopkins; Jonathan Sunkersing; Andrew Jacques
Journal:  J Intensive Care Soc       Date:  2017-02-20

2.  [Cardiogenic shock after drug therapy for atrial fibrillation with tachycardia : Case report of an 89-year-old woman].

Authors:  H Fey; M Jost; A T Geise; T Bertsch; M Christ
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-10-06       Impact factor: 0.840

3.  In Vitro Studies Indicate Intravenous Lipid Emulsion Acts as Lipid Sink in Verapamil Poisoning.

Authors:  Dmytro O Kryshtal; Sheila Dawling; Donna Seger; Bjorn C Knollmann
Journal:  J Med Toxicol       Date:  2016-06

4.  A multifaceted approach to calcium channel blocker overdose: a case report and literature review.

Authors:  Robert Burkes; Gregg Wendorf
Journal:  Clin Case Rep       Date:  2015-05-18

5.  Comparison of Effects of Separate and Combined Sugammadex and Lipid Emulsion Administration on Hemodynamic Parameters and Survival in a Rat Model of Verapamil Toxicity.

Authors:  Serkan Tulgar; Halil Cihan Kose; Isılay Demir Piroglu; Evvah Karakilic; Nagihan Gozde Ates; Ahmet Demir; Ruken Gergerli; Selin Guven; Mustafa Devrim Piroglu
Journal:  Med Sci Monit       Date:  2016-03-25

6.  Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.

Authors:  Maude St-Onge; Kurt Anseeuw; Frank Lee Cantrell; Ian C Gilchrist; Philippe Hantson; Benoit Bailey; Valéry Lavergne; Sophie Gosselin; William Kerns; Martin Laliberté; Eric J Lavonas; David N Juurlink; John Muscedere; Chen-Chang Yang; Tasnim Sinuff; Michael Rieder; Bruno Mégarbane
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

7.  Bilateral blindness secondary to optic nerve ischemia from severe amlodipine overdose: a case report.

Authors:  Raymond Kao; Yves Landry; Genevieve Chick; Andrew Leung
Journal:  J Med Case Rep       Date:  2017-08-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.